Evidence map›Paper›PMID 42064218›Full record

ArticleFrontiers in cellular and infection microbiology2026

Human respiratory syncytial virus regulates the expression of interferon-stimulated genes through modulation of fibrillarin.

José Manuel Ulloa-Aguilar, Victor Javier Cruz-Holguin, Yazmín Rocío Benítez-Zeferino, Edgar Rodrigo Guzmán-Bautista, Julio García-Cordero, Luis Adrián De Jesús-González, Julio Angel Vázquez-Martínez, Edgar Ricardo Vázquez-Martínez, Luis Herrera-Moro Huitron, Alfredo Mosqueda-Gracida and 4 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

José Manuel Ulloa-AguilarLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.
Victor Javier Cruz-HolguinLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.
Yazmín Rocío Benítez-ZeferinoLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.
Edgar Rodrigo Guzmán-BautistaInstituto de Investigación Sobre la Salud Pública, Universidad de la Sierra Sur, Miahuatlan de Porfirio Díaz, Oaxaca, Mexico.
Julio García-CorderoDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Mexico City, Mexico.
Luis Adrián De Jesús-GonzálezUnidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas, Mexico.
Julio Angel Vázquez-MartínezDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, United States.
Edgar Ricardo Vázquez-MartínezUnidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología - Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Luis Herrera-Moro HuitronLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.
Alfredo Mosqueda-GracidaLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.
Monica Viveros-RogelDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Moises Vergara-MendozaDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Roxana Uri Miranda-LabraDepartamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Unidad Iztapalapa, Mexico City, Mexico.
Moises León-JuárezLaboratorio de Virología Perinatal y Diseño Molecular de Antigenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Human respiratory syncytial virus (RSV) is one of the main viral agents associated with the development of acute respiratory infections (ARIs), particularly during infancy and early childhood. RSV vaccine have recently been approved, however, are currently limited to older adults and pregnant women, with no approval for young children. In the absence of broadly effective and accessible preventive or therapeutic options for this vulnerable population, understanding the biology of RSV represents a critical alternative strategy. While several viral proteins have been reported to regulate the expression of interferon-stimulated genes (ISGs) to evade the host antiviral immune response, recent studies have shown that some viruses can also recruit host cellular proteins to facilitate their replication or modulate antiviral pathways. In this context, the nucleolus, and its resident proteins, such as fibrillarin (FBL), have been suggested to play a role in the regulation of inflammatory responses and in the activation of genes involved in early antiviral defense mechanisms. Methods: To analyze FBL expression under viral infection conditions, immunofluorescence assays (IFA) and Western blot (WB) analyses were performed. The effects of FBL depletion were evaluated using WB, IFA, RT-qPCR, and lytic plaque assays. Three experimental conditions were established: uninfected A549 cells (mock), RSV-infected cells, and RSV-infected cells with FBL knockdown. To determine the relationship between FBL and interferon-stimulated gene (ISG) expression, RT-qPCR assays were performed to quantify the expression levels of selected ISGs, including OAS1, OAS2, IFIT3, PKR, and RIG-I. Additionally, FBL-knockdown cells were transfected with a GFP-FBL construct to restore FBL expression, and the recovery of RSV infection was evaluated by IFA, RT-qPCR, and plaque-forming unit (PFU) assays. Moreover, the downregulation of ISG expression in cells with restored GFP-FBL was assessed by RT-qPCR. Finally, p53 knockdown assays were performed to evaluate changes in FBL expression and the reduction of RSV infection, as determined by WB. Results: RSV infection was found to induce FBL expression at early stages of infection in A549 cells. Additionally, our data suggest that FBL suppresses the expression of interferon-stimulated genes (ISGs). Conversely, silencing of FBL significantly reduced RSV infection. Importantly, this reduction in viral replication was associated with increased ISG expression in FBL-deficient A549 cells upon RSV infection. Furthermore, exogenous expression of FBL in FBL-knockdown cells restored RSV infection and led to a concomitant reduction in ISG expression following the recovery of FBL protein levels. Finally, p53-knockdown cells reduced viral protein M2-1 levels without affecting FBL expression, pointing to the involvement of other regulatory mechanism controlling FBL during RSV infection. Conclusion: Our data show that RSV infection promotes the expression of the FBL protein, creating an environment devoid of early antiviral response mediators such as ISGS.

Indexed as

Chromosomal Proteins, Non-HistoneGene Expression RegulationHost-Pathogen InteractionsInterferonsRespiratory Syncytial Virus, HumanA549 CellsCell LineHumansRespiratory Syncytial Virus InfectionsVirus ReplicationChromosomal Proteins, Non-HistonefibrillarinInterferonsARISfibrillarininnate immunityISGsnucleolusRSV

Identifiers

PMID42064218
PMCPMC13125114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.